Acl top automated analyzer

The inclusion criteria of this study were as follows: (i) age > 18 years, (ii) definitive diagnosis of sepsis based on the International Classification of Diseases (ICD 9) code 995.92 (sepsis) and 785.52 (septic shock), which are currently recommended by the Sepsis-3, and (iii) at least one DD value measured within 24 hours after ICU admission (in patients with many sequential DD values available, the first one measured at ICU admission was selected). The plasma DD was assayed using HemosIL D-Dimer HS 500 kit on the Instrumentation Laboratory ACL TOP automated analyzer (Instrumentation Laboratory, Lexington, USA).
The following additional information was then extracted from the database: demographic characteristics, results of laboratory testing and blood gas analysis, severity scores, treatment modalities, comorbidity, length of stay in the ICU, and outcome (i.e., in-hospital death). All laboratory tests, except DD, were collected in the first 24 hours of patient admission. The sequential organ failure score (SOFA) and simplified acute physiology score (SAPSII) scores were calculated as previously described (18 (link), 19 (link)).

Following overnight fasting, blood was drawn for the measurement of blood glucose, hematocrit (Ht), platelet, plasminogen activator inhibitor 1 (PAI-1), fibrinogen, factor VII (FVII), factor VIII (FVIII) and prothrombin fragment 1 + 2 (F1 + 2), and for assessment using T-TAS.
Glucose levels were measured using a GA echo buffer solution, Glucose BP standard solution and automated glucose analyzer GA08III (A&T corporation, Kanagawa, Japan). The LPIA·tPAI test with the automated immunoanalyzer STACIA (LSI Medience Corporation, Tokyo, Japan) for PAI-1, Thrombo check Fib (L) with CS-5100 Automated Coagulation Analyzer (Sysmex Corporation, Hyogo, Japan) for fibrinogen, HemosIL RecombiPlasTin or HemosIL Synth Asil with ACL TOP automated analyzer (Instrumentation Laboratory, Bedford, MA) for FVII or FVII and Enzygnost with Microplate Reader Emax (Molecular Devices Japan, Tokyo, Japan) for F1 + 2 were applied respectively.

D-dimers were measured to determine whether edaravone attenuates the inhibition of alteplase-induced fibrinolysis by H₂O₂. Four-hundred microliter aliquots of 30% human PPP pooled from all 10 volunteers and TBSTC were prepared. After incubation at 37°C for 15 min, H₂O₂ (100 μM), edaravone (60 nM), or vehicle was added. After incubation at 37°C for 10 min, alteplase (100 IU/ml), plasmin (250 μg/ml), or vehicle was added. After fibrin deposition had occurred by incubating at 37°C for 10 min, aprotinin (400KIU/ml) was added. After centrifugation at maximum speed for 5 min, the concentration of D-dimers was measured using an ACL TOP automated analyzer (Instrumentation Laboratory, Bedford, MA) (n = 5).